Resources | Press Releases |Press Release

Venn Life Sciences would like to announce the appointment of Dale Trask as Vice President Global Business Development, marking an important phase in the company’s growth. Mr. Trask brings extensive experience in Clinical Research Organisation (CRO) business development and will be responsible for enhancing Venn’s business partnerships, strategic relationships and growth into new markets.

"Dale's broad experience in CRO business relationships will make him an outstanding member of Venn's team. He will help ensure that our strategic business relationships continue to grow as we deliver competitive solutions to our pharmaceutical and biotech customers," said Tony Richardson, Chief Executive Officer of Venn Life Sciences

Mr. Trask joins Venn Life Sciences with more than ten years of business development and strategic planning experience in the Biopharma and CRO industries. His previous role with Excel PharmaStudies, a Chinese based full service CRO, focused on the rapidly developing clinical research markets in China and Asia Pacific. Prior to Excel, he was Director of Global Business activities at Evidence Clinical and Pharmaceutical Research where he successfully launched business and clinical initiatives for this Russian based CRO in the US, Europe and Asia.

"I am very excited to be part of an organization where we are all working toward the same goals and serving our customers in the clinical trials community with smart and effective solutions," said Mr. Trask. "I will be working to build business connections and partnerships to extend Venn's market with its range of therapeutic experience and trial services."

Dale resides in Boston, Massachusetts where he earned his Master of Business Administration (MBA) degree from Babson College, Wellesley MA and is an active member of several life science industry groups.

Venn Life Sciences

Venn Life Sciences is a rapidly growing Clinical Research Organisation (CRO) with offices in Dublin, Montreal, Switzerland, Mexico and Australia. The company’s clinical trial expertise spans a wide range of therapeutic indications with industry veterans heading up the regional offices. Venn has an aggressive expansion strategy over the coming years with further acquisitions planned for 2010. Venn has successfully completed clinical trials in multiple countries with coverage spanning five continents.